R
Rachel Leeson
Researcher at Harvard University
Publications - 9
Citations - 1861
Rachel Leeson is an academic researcher from Harvard University. The author has contributed to research in topics: Pichia pastoris & Comparative genomics. The author has an hindex of 7, co-authored 9 publications receiving 1173 citations. Previous affiliations of Rachel Leeson include University of Duisburg-Essen & Massachusetts Institute of Technology.
Papers
More filters
Journal ArticleDOI
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Livnat Jerby-Arnon,Parin Shah,Michael S. Cuoco,Christopher Rodman,Mei-Ju Su,Johannes C. Melms,Rachel Leeson,Abhay Kanodia,Shaolin Mei,Jia-Ren Lin,Shu Wang,Bokang Rabasha,David Liu,Gao Zhang,Claire Margolais,Orr Ashenberg,Patrick A. Ott,Elizabeth I. Buchbinder,Rizwan Haq,F. Stephen Hodi,Genevieve M. Boland,Ryan J. Sullivan,Dennie T. Frederick,Benchun Miao,Tabea Moll,Keith T. Flaherty,Meenhard Herlyn,Russell W. Jenkins,Rohit Thummalapalli,Monika S. Kowalczyk,Israel Cañadas,Bastian Schilling,Bastian Schilling,Adam N.R. Cartwright,Adrienne M. Luoma,Shruti Malu,Patrick Hwu,Chantale Bernatchez,Marie Andrée Forget,David A. Barbie,Alex K. Shalek,Itay Tirosh,Peter K. Sorger,Kai W. Wucherpfennig,Eliezer M. Van Allen,Dirk Schadendorf,Bruce E. Johnson,Asaf Rotem,Asaf Rotem,Orit Rozenblatt-Rosen,Levi A. Garraway,Charles H. Yoon,Charles H. Yoon,Benjamin Izar,Aviv Regev +54 more
TL;DR: A resistance program expressed by malignant cells that is associated with T cell exclusion and immune evasion is identified, and this study provides a high-resolution landscape of ICI-resistant cell states, identifies clinically predictive signatures, and suggests new therapeutic strategies to overcome immunotherapy resistance.
Journal ArticleDOI
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
Viktor A. Adalsteinsson,Viktor A. Adalsteinsson,Gavin Ha,Gavin Ha,Samuel S. Freeman,Samuel S. Freeman,Atish D. Choudhury,Daniel G. Stover,Heather A. Parsons,Gregory Gydush,Sarah C. Reed,Denisse Rotem,Justin Rhoades,Denis Loginov,Denis Loginov,Dimitri Livitz,Daniel Rosebrock,Daniel Rosebrock,Ignaty Leshchiner,Jaegil Kim,Chip Stewart,Mara Rosenberg,Joshua M. Francis,Joshua M. Francis,Cheng-Zhong Zhang,Cheng-Zhong Zhang,Ofir Cohen,Ofir Cohen,Coyin Oh,Huiming Ding,Paz Polak,Paz Polak,Max Lloyd,Sairah Mahmud,Karla Helvie,Margaret S. Merrill,Rebecca A. Santiago,Edward P. O’Connor,Seong Ho Jeong,Rachel Leeson,Rachel M. Barry,Joseph F. Kramkowski,Zhenwei Zhang,Laura Polacek,Jens G. Lohr,Jens G. Lohr,Molly Schleicher,Emily Lipscomb,Andrea Saltzman,Nelly Oliver,Lori Marini,Adrienne G. Waks,Adrienne G. Waks,Lauren C. Harshman,Sara M. Tolaney,Eliezer M. Van Allen,Eric P. Winer,Nan Lin,Mari Nakabayashi,Mary-Ellen Taplin,Cory M. Johannessen,Levi A. Garraway,Todd R. Golub,Jesse S. Boehm,Nikhil Wagle,Nikhil Wagle,Gad Getz,Gad Getz,J. Christopher Love,J. Christopher Love,Matthew Meyerson +70 more
TL;DR: In this paper, a software called ichorCNA was proposed to quantitatively measure tumor content in cfDNA from 0.1× coverage whole-genome sequencing data without prior knowledge of tumor mutations.
Journal Article
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
Gavin Ha,Samuel S. Freeman,Atish D. Choudhury,Daniel G. Stover,Heather A. Parsons,Gregory Gydush,Sarah C. Reed,Denisse Rotem,Justin Rhoades,Dimitri Livitz,Daniel Rosebrock,Ignaty Leshchiner,Jaegil Kim,Chip Stewart,Mara Rosenberg,Joshua M. Francis,Cheng-Zhong Zhang,Ofir Cohen,Coyin Oh,Paz Polak,Max Lloyd,Sairah Mahmud,Karla Helvie,Margaret S. Merrill,Rebecca A. Santiago,Edward P. O’Connor,Seong Ho Jeong,Joseph F. Kramkowski,Zhenwei Zhang,Laura Polacek,Jens G. Lohr,Molly Schleicher,Emily Lipscomb,Andrea Saltzman,Nelly Oliver,Lori Marini,Adrienne G. Waks,Lauren C. Harshman,Sara M. Tolaney,Eliezer M. Van Allen,Eric P. Winer,Nan Lin,Mari Nakabayashi,Mary-Ellen Taplin,Cory M. Johannessen,Levi A. Garraway,Todd R. Golub,Jesse S. Boehm,Nikhil Wagle,Gad Getz,Matthew Meyerson,Viktor A. Adalsteinsson,Denis Loginov,Huiming Ding,Rachel Leeson,Rachel M. Barry,John C Love +56 more
TL;DR: The authors provide methods to identify patients eligible for comprehensive cfDNA profiling, revealing its applicability to many patients, and demonstrate high concordance of cfDNA and metastatic tumor whole-exome sequencing.
Journal ArticleDOI
A single-cell landscape of high-grade serous ovarian cancer.
Benjamin Izar,Itay Tirosh,Elizabeth H. Stover,Isaac Wakiro,Michael S. Cuoco,Idan Alter,Christopher Rodman,Rachel Leeson,Mei-Ju Su,Parin Shah,Marcin P. Iwanicki,Sarah R. Walker,Abhay Kanodia,Johannes C. Melms,Shaolin Mei,Jia-Ren Lin,Caroline B. M. Porter,Michal Slyper,Julia Waldman,Livnat Jerby-Arnon,Orr Ashenberg,Titus J. Brinker,Caitlin E. Mills,Meri Rogava,Sébastien Vigneau,Peter K. Sorger,Levi A. Garraway,Panagiotis A. Konstantinopoulos,Joyce F. Liu,Ursula A. Matulonis,Bruce E. Johnson,Orit Rozenblatt-Rosen,Asaf Rotem,Asaf Rotem,Aviv Regev +34 more
TL;DR: Significant inter-patient variability is found in the composition and functional programs of ascites cells, including immunomodulatory fibroblast sub-populations and dichotomous macrophage populations, which contributes to resolving the HSGOC landscape and provides a resource for the development of novel therapeutic approaches.
Journal ArticleDOI
Comparative genomics and transcriptomics of Pichia pastoris
Kerry R. Love,Kartik A. Shah,Charles A. Whittaker,Jie Wu,M. Catherine Bartlett,Duanduan Ma,Rachel Leeson,Margaret Priest,Jonathan Borowsky,Sarah Young,J. Christopher Love,J. Christopher Love +11 more
TL;DR: In this article, a comparative analysis of the genomic features of the three most commonly used strains comprising the tradename Pichia: K. pastoris wild-type, K. phaffii GS115, and K. prophetis GS115 is presented.